Astrazeneca

AZN: 7,690.00 +116.00 (+1.53%) delayed: 21 Feb 2020, 18:30

Trade now

Astrazeneca Fundamentals

Share Price Information

Name Astrazeneca
Epic AZN
Sector Pharmaceuticals
ISIN GB0009895292
Activites AstraZeneca plc is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Index FTSE 100

Key numbers

Latest Share price (p) 7,690.00 Net gearing (%) 67.47
Market capitalisation (£m) 99,923.07 Gross gearing (%) 76.22
Shares in issue (m) 1,312.19 Debt ratio 66.26
P/E ratio 73.93 Debt-to-equity ratio 0.61
Total dividends per share (p) 218.30 Assets / equity ratio 4.21
Dividend yield (%) 2.87 Price to book value 6.85
Dividend cover 0.47 ROCE (%) 3.58
Earning per share (p) 103.00 EPS growth (%) -39.41
52-week high / low (p) 7,948.00 / 5,626.00 DPS growth (%) 1.44

Results at a glance

Date Type Turnover (£m) Profit (£m) Basic EPS Currency
31 Dec 2019 Full Year 24,384 1,227 103.00 USD
31 Dec 2018 Full Year 22,090 2,050 170.00 USD
31 Dec 2017 Full Year 22,465 2,868 237.00 USD

Dividend history

Period Ex-date Pay-date Net dividend Currency Total for year
H2 Dividend 27 Feb 2020 30 Mar 2020 146.40 GBX 218.30
H1 Dividend 08 Aug 2019 09 Sep 2019 71.90 GBX 0.00
H2 Dividend 28 Feb 2019 27 Mar 2019 146.80 GBX 215.20
H1 Dividend 09 Aug 2018 10 Sep 2018 68.40 GBX 0.00
H2 Dividend 15 Feb 2018 19 Mar 2018 133.60 GBX 202.50
H1 Dividend 10 Aug 2017 11 Sep 2017 68.90 GBX 0.00
H2 Dividend 16 Feb 2017 20 Mar 2017 150.20 GBX 218.90
H1 Dividend 11 Aug 2016 12 Sep 2016 68.70 GBX 0.00
H2 Dividend 18 Feb 2016 21 Mar 2016 131.00 GBX 188.50
H1 Dividend 13 Aug 2015 14 Sep 2015 57.50 GBX 0.00
H2 Dividend 19 Feb 2015 23 Mar 2015 125.00 GBX 178.10

Contact details

Company name AstraZeneca
Address 15 Stanhope Gate, London W1K 1LN.
Telephone +44 (0)20 7304 5000
Website http://www.astrazeneca.com/

Advisors

Company's broker Morgan Stanley Securities
Company's joint broker n/a
NOMAD n/a
Registrar Equiniti
Auditors KPMG Audit
Solicitors n/a

Directors

Appointed Director Position
01 Oct 2012 Pascal Claude Roland Soriot Chief Executive Officer
01 Nov 2013 Marc Pierre Jean Dunoyer Chief Financial Officer
26 Apr 2012 Leif Valdemar Johansson Non-Executive Chairman
01 Oct 2017 Sherilyn Dawn McCoy Non-Executive Director
01 Jan 2019 Tony Shu Kam Mok Non-Executive Director
01 Jun 2017 Prof Sabera Nazneen Rahman Non-Executive Director
06 Apr 1999 Marcus Wallenberg Non-Executive Director
01 Sep 2019 Michel Roger Demaré Non-Executive Director
01 Dec 2017 Deborah DiSanzo Non-Executive Director
26 Apr 2012 Graham Andrew Chipchase Non-Executive Director
27 Apr 2017 Philip Arthur John Broadley Non-Executive Director
26 Apr 2012 Prof Geneviève Bernadette Berger Non-Executive Director

Company financials

Assets (£m) 2019 2018 2017
Reporting date 31 Dec 2019 31 Dec 2018 31 Dec 2017
Tangible assets 7,688 7,421 7,615
Intangible asssets and goodwill 33,148 33,666 38,013
Investments and other non-current assets 4,978 3,973 4,576
Total non-current assets 45,814 45,060 50,204
Inventory / work in progress 3,193 2,890 3,035
Trade and other receivables 5,761 5,574 5,009
Cash and equivalents 5,369 4,831 3,324
Other current assets and asset held for resale 1,240 2,296 1,782
Total of all assets 61,377 60,651 63,354
Liabilities (£m) 2019 2018 2017
Short term liabilities 18,117 16,292 16,383
Long term liabilities 28,664 30,315 30,329
Other liabilites / pension etc 0 0 0
Total of all liabilities 46,781 46,607 46,712
Net assets (£m) 2019 2018 2017
Net assets 14,596 14,044 16,642
Equity (£m) 2019 2018 2017
Share capital 328 317 317
Minority interests 1,469 1,576 1,682
Retained earnings 2,812 5,683 8,221
Share premium account 7,941 4,427 4,393
Other equity 2,046 2,041 2,029
Total equity 14,596 14,044 16,642
Cash Flow (£m) 2019 2018 2017
Cash from operating activities 2,969 2,618 3,578
Cashflow before financing 2,312 3,581 1,250
Increase / decrease in Cash 547 1,537 -1,686
Income (£m) 2019 2018 2017
Turnover 24,384 22,090 22,465
Cost of sales 4,921 4,936 4,318
Gross profit 19,463 17,154 18,147
Operating profit 2,924 3,387 3,677
Pre-tax profit 1,548 1,993 2,227
Profit / loss for the year 1,227 2,050 2,868